Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease

Imagem de Miniatura
Arquivos
art_STEFANO_Usefulness_of_collagen_type_IV_in_the_detection_2021.PDF (1.01 MB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
LARGURA, Alvaro
ARRESE, Marco
Citação
ANNALS OF HEPATOLOGY, v.20, article ID 100253, 6p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction/aims: Liver fibrosis assessment is a key issue in the evaluation of nonalcoholic fatty liver disease (NAFLD) patients. In the present study, we aimed to validate a noninvasive marker panel to assess significant and advanced fibrosis in these patients. Method: 126 biopsy-proven NAFLD patients were included. NAFLD diagnosis was based on histological criteria. Fibrosis stages were determined according to NASH-Clinical Research Network criteria. Clinical and laboratorial data were collected during the interval of three months before or after liver biopsy. Histological fibrosis stages were classified as significant fibrosis (F2-F4) and advanced fibrosis (F3-F4). Five serum biomarkers [hyaluronic acid (HA), collagen type IV (cIV), procollagen type III (PC III), laminin (LN) and cholylglycine (CG)] were assessed by chemiluminescence immunoassays. Results: Most patients were female (61.61%), mean age: 55.7 +/- 9.13 years old and mean BMI was 32.1 +/- 5.9 kg/m(2). Prevalence of diabetes, dyslipidemia, arterial hypertension, and metabolic syndrome was 68.75%, 82.29%, 63.54% and 81.05%, respectively. Patients with cIV above 30 ng/mL had a 5.57-times (IC: 1.86-16.69) the chance of having significant fibrosis and 7.61-times (IC: 2.27-25.54) the chance of having advanced fibrosis versus patients with values below 30 ng/mL. HA, PC III, LN and CG did not detect the presence of significant and advanced fibrosis. The AUROC of clV for detection of significant (0.718) and advanced fibrosis (0.791) was better than that of other serum biomarkers. Conclusion: Type 4 collagen could predict the presence of significant and advanced fibrosis in NAFLD patients and it would be a useful tool in routine clinical practice. (C) 2020 Fundacion Clinica Medica Sur, A.C.
Palavras-chave
Nonalcoholic fatty liver disease, serum biomarker, Liver fibrosis, Type 4 collagen
URI
https://observatorio.fm.usp.br/handle/OPI/39353
Referências
  1. Al Knawy B, 2007, LIVER INT, V27, P1166, DOI 10.1111/j.1478-3231.2007.01592.x
  2. Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
  3. Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043
  4. [Anonymous], 2020, DIABETES CARE, V43, pS1, DOI [10.2337/dc20-SINT, 10.2337/dc20-Sint]
  5. Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
  6. Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
  7. Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001
  8. Cotter TG, 2020, GASTROENTEROLOGY, V158, P1851, DOI 10.1053/j.gastro.2020.01.052
  9. Dulai PS, 2017, HEPATOLOGY, V65, P1557, DOI 10.1002/hep.29085
  10. Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368
  11. Eng J., 2014, ROC ANAL WEB BASED C
  12. Estes C, 2018, J HEPATOL, V69, P896, DOI 10.1016/j.jhep.2018.05.036
  13. Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466
  14. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020
  15. Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
  16. Gudowska M, 2017, GASTROENTEROL REV, V12, P203, DOI 10.5114/pg.2017.70474
  17. HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
  18. Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
  19. Itoh Y, 2018, HEPATOL RES, V48, P1099, DOI 10.1111/hepr.13226
  20. Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
  21. Lesmana CRA, 2009, J DIGEST DIS, V10, P201, DOI 10.1111/j.1751-2980.2009.00386.x
  22. Loomba R, 2020, GUT, V69, P1343, DOI 10.1136/gutjnl-2018-317593
  23. McPherson S, 2013, EUR J GASTROEN HEPAT, V25, P652, DOI 10.1097/MEG.0b013e32835d72cf
  24. Miele L, 2009, TRANSL RES, V154, P194, DOI 10.1016/j.trsl.2009.06.007
  25. Mizuno M, 2017, HEPATOL RES, V47, P216, DOI 10.1111/hepr.12710
  26. Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623
  27. Okanoue T, 2018, J GASTROENTEROL, V53, P129, DOI 10.1007/s00535-017-1355-9
  28. Arab JP, 2018, ANN HEPATOL, V17, P899, DOI 10.5604/01.3001.0012.7188
  29. Parsian H, LIVER BIOPSY
  30. Rosenberg WMC, 2004, GASTROENTEROLOGY, V127, P1704, DOI 10.1053/j.gastro.2004.08.052
  31. Rostami Z, 2013, HEPAT MON, V13, DOI [10.5812/hepatmon.9611, 10.5812/hepatmon.13787]
  32. Rustagi Tarun, 2010, Trop Gastroenterol, V31, P199
  33. Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256
  34. Sebastiani G, 2006, WORLD J GASTROENTERO, V12, P3682, DOI 10.3748/wjg.v12.i23.3682
  35. Srivastava A, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1039-4
  36. Tanwar S, 2013, HEPATOLOGY, V57, P103, DOI 10.1002/hep.26030
  37. Valva P, 2018, EUR J GASTROEN HEPAT, V30, P637, DOI 10.1097/MEG.0000000000001079
  38. Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
  39. Younossi Z, 2019, HEPATOLOGY, V69, P2672, DOI 10.1002/hep.30251
  40. Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03